FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy

TITUSVILLE, NJ, June 30, 2005 -- The U.S. Food and Drug Administration (FDA) yesterday approved a new use for TOPAMAX (topiramate) Tablets and TOPAMAX (topiramate capsules) Sprinkle Capsules as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than two seizures in the three months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

"Anti-epilepsy medications, or neuromodulators, are selected based on seizure type; however, the specific seizure type may not always be obvious at the time of diagnosis," said Tracy Glauser, M.D., director of the Comprehensive Epilepsy Center at the Cincinnati Childrens Hospital. "A treatment like TOPAMAX, which provides coverage for both partial-onset and primarily generalized tonic-clonic seizures, offers doctors an option in situations where differentiating between these seizure types is difficult."

Epilepsy is characterized by seizures, which are abnormal electrical discharges in the brain that temporarily disrupt normal brain function. Seizures are classified as "generalized," originating in both sides of the brain simultaneously, or "partial-onset," starting in one area of the brain.

In a double-blind clinical trial, 470 patients with partial-onset or primary generalized tonic-clonic seizures were randomized to treatment with 50 mg or 400 mg/day of TOPAMAX. The primary efficacy assessment was a group comparison of time to first seizure during the double-blind phase of the study. Comparison of the Kaplan-Meier survival curves of time to first seizure favored the 400 mg/day group over the 50mg/day group. The recommended dose for monotherapy in patients 10 years of age and older is 400 mg/da

Contact: Debbie Harvey
Golin/Harris International

Page: 1 2 3

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
3. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
4. VCR -- FDA approves home discharge for US patients
5. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
6. FDA approves Vectibix to treat patients with metastatic colorectal cancer
7. 5,000 rare diseases need drugs, but Europe only approves a handful each year
8. FDA approves room temperature storage of ZLB Behrings Helixate FS
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Majority of herb users dont follow evidence-based indications, researchers find

Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker ... order to date. , The order will be from the China Disabled Persons’ ... Implant System is an effective solution for children and adults suffering from severe ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Brooke Bennett are collaborating with brands across various categories through traditional and social ... make up an elite group of Gold Medal Moms who can connect with ...
(Date:11/30/2015)... ... December 01, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting 850,000 members and over 200 ...
(Date:11/30/2015)... Alexandria, VA (PRWEB) , ... November 30, 2015 ... ... Applied Research Foundation (Meso Foundation) released information for caregivers and held two webinars ... webinars are available on demand free of charge at http://www.curemeso.org/caregivers . , ...
(Date:11/30/2015)... ... ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from INDE Broadcast ... collection of interactive exhibits within the Kids In Charge! building. In collaboration with the ... closer than ever to a range of animals as they drink, sleep and play ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... Detroit Free Press as a Top Workplace , among ... to work for in 2015. ... winners annually, based on employee surveys rating company leadership, career ... are based solely on employee feedback. The survey is conducted ...
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... , November 30, 2015 global cell culture ... US$6.1 bn to US$11.3 bn by 2022 at a CAGR of ... expected to grow from its 2013 value of US$6.1 bn to ... --> Transparency Market Research has announced the release of a ... to the report, titled ,Cell Culture Market - Global Industry Analysis, ...
Breaking Medicine Technology:
Cached News: